

WEDNESDAY, JULY 8 2026, MORNING SESSIONS

6:00 AM **BREAKFAST**

6:30 AM **WELCOME & INTRODUCTIONS**
Vinay Jain/John Heymach/Natasha Leighl/Sandip Patel/Joshua Sabari

KEYNOTES

6:45 AM Keynote: Lessons learned — my life journey *Ravi Salgia*

6:55 AM The long journey of attitudes and treatment approaches for head and neck cancer *Everett Vokes*

7:05 AM **DISCUSSION**

EGFR INHIBITORS IN ADJUVANT AND NEOADJUVANT SETTINGS

Jamie Chaft

7:20 AM Evaluating the impact of EGFR expression and location on the efficacy of therapy *Matthew Lee*

7:27 AM Lessons learned from NeoADAURA and how to implement osimertinib in the neoadjuvant space *Jamie Chaft*

7:34 AM Findings from a clinical trial of neoadjuvant osimertinib prior to chemoradiation in EGFR+ NSCLC *Jacqueline Aredo*

7:41 AM Role of consolidation in EGFR mutant oligometastatic disease *Urs Weber*

7:48 AM Ziplertinib, a TKI targeting EGFR exon 20 and PACC mutations in the neoadjuvant setting for NSCLC *Arjan Gower*

7:55 AM First-in-human trial of lurbinectedin plus osimertinib in transformed SCLC *Triparna Sen*

8:02 AM Amivantamab: Strategic approaches to improving outcomes and tolerance *Helen Ross*

8:09 AM **DISCUSSION**

KRAS G12C TARGETING AGENTS

Jonathan Riess

8:25 AM Sotorasib in G12C mutant NSCLC: The VA experience *Michael Kelley*

8:32 AM Update on adagrasib plus pembrolizumab combination in KRAS G12C NSCLC *Joshua Sabari*

8:39 AM Olomorasib + pembrolizumab +/- chemotherapy in KRAS G12C-mutant NSCLC *Umit Tapan*

8:46 AM Intracranial efficacy of olomorasib, in KRAS G12C-mutant NSCLC with untreated brain metastases *Timothy Burns*

8:53 AM **DISCUSSION**

HER2 KINASE INHIBITORS AND ADCs FOR HER2/HER3 IN NSCLC

Misako Nagasaka

9:10 AM Recent data with zongertinib in newly diagnosed HER2-mutant non-small-cell lung cancer *Joshua Sabari*

9:17 AM Sevabertinib in previously treated HER2 mutated NSCLC *Xiuning Le*

9:24 AM Comprehensive structural/ resistance dataset across all HER2 drugs *John Heymach*

9:31 AM HER2-selective TKI with CNS penetration; spares WT EGFR (NVL-330) *Xiuning Le*

9:38 AM **DISCUSSION**

9:55 AM **BREAK AND GROUP PHOTO**

DRUGS TARGETING EGFR AND MET

John Heymach

10:15 AM EGFR resistance in NSCLC: How to decide what comes next *Julia Rotow*

10:22 AM APO pathway (AICDA/cytidine deamination) as a mechanism of on-target EGFR resistance *Khaled Hassan*

10:29 AM Amivantamab for treatment of MET-amplified relapsed/refractory NSCLC *Richard Hall*

10:36 AM Subcutaneous amivantamab (PALOMA-2): Is subQ not just easier but pharmacodynamically better? *Natasha Leighl*

10:43 AM Subcutaneous amivantamab / lazertinib in newly diagnosed NSCLC *Erminia Massarelli*

10:50 AM Development of an AI model to identify patients who will respond to EGFR-targeted monotherapy vs. combination regimens *Fionnuala Crowley*

10:57 AM ADCs targeting MET (Teliso-V and Teliso-A) *Timothy Burns*

11:04 AM **DISCUSSION**

OPTIMIZING TARLATAMAB IN THE TREATMENT SETTING

Millie Das

11:20 AM Tarlatamab as a monotherapy for R/R SCLC *Bingnan Zhang*

11:27 AM Outcomes from real-world experience with tarlatamab in SCLC *Richard Hall*

11:34 AM Findings from a retrospective analysis of tarlatamab safety and efficacy in a population of SCLC patients in the VA system *Michael Kelley*

11:41 AM Transcription factor subtype governs response and resistance to tarlatamab *Matthew Oser*

11:48 AM **DISCUSSION**

WEDNESDAY, JULY 8 2026, AFTERNOON SESSIONS

12:05 PM	WORKING LUNCH SESSION: INDUSTRY PIPELINE PRESENTATIONS (MODERATED BY VINAY JAIN)	<i>Vinay Jain</i>
12:15 PM	Johnson & Johnson	<i>John Eckardt</i>
12:25 PM	Pfizer Oncology	<i>Linh Alejandro</i>
12:35 PM	Jazz Pharmaceuticals	<i>Janki Bharwada</i>
12:45 PM	Eli Lilly	<i>Lee James</i>
12:55 PM	Nuvalent	<i>Kirsten Duncan</i>
1:05 PM	Amgen: Ras pipeline	<i>Christine Ardito-Abraham</i>

EMERGING DLL3-TARGETING AGENTS IN SCLC

Lauren Byers

1:15 PM	Obrixtamig (BI 764532): A DLL3 x CD3 bispecific	<i>Joshua Sabari</i>
1:22 PM	ZG006, a trispecific with targeting of CD3 and biparatopic targeting of DLL3 in SCLC	<i>Bingnan Zhang</i>
1:29 PM	Zocilurtatug pelitecan (ZL-1310), an anti-DLL3 antibody-drug conjugate in development for SCLC	<i>Melinda Hsu</i>
1:36 PM	Current data for IBI3009, an anti-DLL3 ADC in development for advanced SCLC and other neuroendocrine tumors	<i>Zhaohui Arter</i>
1:43 PM	DISCUSSION	

CHECKPOINT INHIBITORS IN NSCLC/ HNSCC

Sandip Patel

2:00 PM	Optimizing immune checkpoint therapy in periradiation therapy for NSCLC	<i>Henry Park</i>
2:07 PM	A multiomic analysis to assess mechanisms of resistance to immune checkpoint inhibition in NSCLC	<i>Valsamo Anagnostou</i>
2:14 PM	Addition of PD-1 to cetuximab in head and neck cancer	<i>Assuntina (Tina) Sacco</i>
2:21 PM	Emerging data for gotistobart (BNT316/ONC392), a novel pH-activated anti-CTLA4 for NSCLC	<i>Zhonglin Hao</i>
2:28 PM	Long-term and late toxicities in survivors post-checkpoint inhibitors — cardiac disease and beyond	<i>Melinda Hsu</i>
2:35 PM	Outpatient monitoring for detection of ICI-induced pneumonitis	<i>Antonious Hazim</i>
2:42 PM	MDT-BRIDGE, neoadjuvant durvalumab + platinum- chemotherapy stage IIB-IIIB NSCLC	<i>Stephen Swisher</i>
2:49 PM	The potential role of multi-site SBRT with immune checkpoint inhibitors for first line metastatic NSCLC	<i>Aditya Juloori</i>
2:56 PM	Rationale for targeting LAG-3 in large cell neuroendocrine carcinomas	<i>Abdul Rafah Naqash</i>
3:03 PM	DISCUSSION	

MOLECULAR TARGETS IN SCLC

Misty Shields

3:15 PM	Genomics of chemotherapy and chemo+IO resistance in SCLC	<i>Triparna Sen</i>
3:22 PM	A retrospective analysis of 70 SCLC patients with Lambert-Eaton syndrome and its impact on treatment efficacy	<i>Michael Kelley</i>
3:29 PM	Tazemetostat with topotecan and pembrolizumab in R/R SCLC	<i>Zhonglin Hao</i>
3:36 PM	The potential role of SMARCA2/4 as a therapeutic target for SCLC	<i>Matthew Oser</i>
3:43 PM	p53 reactivators to improve treatment options	<i>Misty Shields</i>
3:50 PM	DISCUSSION	

THURSDAY, JULY 9, 2026, MORNING SESSIONS

6:00 AM **BREAKFAST**

SURGICAL CONSIDERATIONS
Stephen Swisher

6:30 AM	The role of lung transplantation in lung cancer: A 2026 perspective	<i>Marc de Perrot</i>
6:37 AM	Considerations for lung cancer in the younger population, including aggressive surgical approaches	<i>Mara Antonoff</i>
6:44 AM	Minimally invasive techniques for treating early stage lung cancer	<i>Matthew Bott</i>
6:51 AM	Is TNM obsolete? Revising lung cancer staging for the modern era	<i>James Huang</i>
6:58 AM	Resectability guidelines: How do they help us, and what are we missing?	<i>Erin Gillaspie</i>

7:05 AM **DISCUSSION**

TARGETING ALK
Ravi Salgia

7:25 AM	Using a clinical ALK+ database to improve enrollment approaches to clinical trials for ALK-targeted therapy	<i>Ken Culver</i>
7:32 AM	Lorlatinib 7-year update from the phase 3 CROWN study.	<i>Misako Nagasaka</i>
7:39 AM	Neoadjuvant lorlatinib and alectinib in stage III NSCLC harboring ALK fusion	<i>Jay Lee</i>
7:46 AM	Neladalkib, with activity against diverse ALK fusions and resistance mutations in NSCLC	<i>Elaine Shum</i>

7:53 AM **DISCUSSION**

SCLC - IMMUNOTHERAPY
John Heymach

8:10 AM	From Four Subtypes to One Clear Path: The Future of Personalized SCLC Care	<i>Lauren Byers</i>
8:17 AM	IMforte: The role of atezolizumab + lurbinectedin in frontline SCLC	<i>Jeff Petty</i>
8:24 AM	Biomarker discovery: ISL1 predicts strong responses to a lurbinectedin	<i>Misty Shields</i>
8:31 AM	LB2102, an anti-DLL3 CAR T in development for SCLC	<i>Bingnan Zhang</i>
8:38 AM	BMS 986489 (fucosylated anti-GM1 mAb) + nivolumab in the TIGOS trial for ES-SCLC	<i>Sid Devarakonda</i>
8:45 AM	Inhibitors of cyclin A and B and synthetic lethality in RB-deficient SCLC (CID-078)	<i>Matthew Oser</i>

8:52 AM **DISCUSSION**

TROP2-TARGETED ADCs IN LUNG CANCER
Joshua Sabari

9:10 AM	Biomarkers for antibody-drug conjugates — Trop-2 NMR, QCS, and the HER2 confusion in lung cancer	<i>Fred Hirsch</i>
9:17 AM	Ongoing clinical trials with datopotamab deruxtecan in EGFR-mutant NSCLC	<i>Jonathan Riess</i>
9:24 AM	Current data with sacituzumab govitecan in NSCLC	<i>Sandip Patel</i>
9:31 AM	Outcomes with sacituzumab govitecan in SCLC	<i>Erminia Massarelli</i>
9:38 AM	Sacituzumab tirumotecan plus pembrolizumab in newly diagnosed NSCLC	<i>Natasha Leighl</i>

9:45 AM **DISCUSSION**

10:00 AM **BREAK**

TARGETING ROS1/RET/NRG FUSIONS AND MTAP DELETION
Corey Langer

10:20 AM	Adjuvant selpercatinib in surgically resected Ret fusion NSCLC	<i>Corey Langer</i>
10:27 AM	Taletrectinib: a next-generation ROS1 inhibitor	<i>Misako Nagasaka</i>
10:34 AM	Zidesamtinib, a ROS1 inhibitor in development for ROS1-rearranged advanced or metastatic NSCLC	<i>Elaine Shum</i>
10:41 AM	Outcomes from a retrospective analysis of lung cancer patients treated with zenocutuzumab	<i>Zhaohui Arter</i>
10:48 AM	MTAP deletion as a synthetic lethality approach in lung cancer	<i>Khaled Hassan</i>
10:55 AM	Development and current data for AMG 193, a PRMT5 inhibitor in development for MTAP-deleted cancer	<i>Matthew Lee</i>
11:02 AM	Update on LungMAP: Recently opened arms	<i>Helen Ross</i>

11:09 AM **DISCUSSION**

NOVEL ADCs
Natasha Leighl

11:25 AM	SEZ6 targeting ADC in SCLC (ABBV-706)	<i>Millie Das</i>
11:32 AM	Sigvotatug vedotin (integrin targeting ADC) clinical trials in newly diagnosed NSCLC	<i>Corey Langer</i>
11:39 AM	Emiltatug ledadotin, a B7H-4-targeting ADC in adenoid cystic carcinoma	<i>Renata Ferrarotto</i>
11:46 AM	HLX43 — PDL1-targeted ADC using PD-L1 as a therapeutic receptor to deliver cytotoxic payload	<i>Fred Hirsch</i>
11:53 AM	Fetrastobart vedotin: PDL1-targeted ADC Phase III development	<i>Mehmet Altan</i>

12:00 PM **DISCUSSION**

THURSDAY, JULY 9, 2026, AFTERNOON SESSIONS

12:15 PM LUNCH POSTER SESSION

Vinay Jain

EMERGING RAS-TARGETING AGENTS (RAS ON/OFF, G12D, Q61)

John Heymach

1:00 PM	Biology of RAS mutations in lung cancer	<i>Ravi Salgia</i>
1:07 PM	Mechanisms of resistance to KRAS inhibitors and how to overcome this resistance, including daraxonrasib	<i>Biagio Ricciuti</i>
1:14 PM	Daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC	<i>Joshua Sabari</i>
1:21 PM	Current clinical data for zoldonrasib, a KRAS G12D inhibitor, in previously treated NSCLC with KRAS G12D mutations	<i>Jonathan Riess</i>
1:28 PM	VS-7375, a KRAS G12D inhibitor in early clinical development	<i>Matthew Gumbleton</i>
1:35 PM	ERAS-0015, a pan-RAS molecular glue in advanced or metastatic solid tumors	<i>Erminia Massarelli</i>
1:42 PM	Initial experience with a novel pan-KRAS inhibitor (PF-07934040) in KRAS-mutant NSCLC	<i>Matthew Lee</i>
1:49 PM	Biology and treatment strategies for KRAS Q61H mutations in NSCLC	<i>Haniel Araujo</i>

1:56 PM **DISCUSSION**

EXON 20 AND ATYPICAL EGFR MUTATIONS

Julia Rotow

2:15 PM	How to manage EGFR atypical mutations in NSCLC, including PACC mutations	<i>Julia Rotow</i>
2:22 PM	Update on sunvozertinib for the treatment of NSCLC with EGFR exon 20 mutations	<i>Zhaohui Arter</i>
2:29 PM	Zipalertinib for exon 20 and other challenging EGFR mutations in stage IV NSCLC	<i>Jacqueline Aredo</i>
2:36 PM	Silevertinib and BH-30643, next-generation EGFR inhibitors	<i>Xiuning Le</i>

2:43 PM **DISCUSSION**

OPEN QUESTIONS IN RADIATION THERAPY

Steven Lin

3:00 PM	Timing of checkpoint therapy with radiation: What have we learned, and where are we going?	<i>James Urbanic</i>
3:07 PM	Role of chemoimmunotherapy before chemoradiotherapy for stage III unresectable NSCLC	<i>Aditya Juloori</i>
3:14 PM	Selecting patients who might benefit from local consolidation? Insights on the NRG trial	<i>Stephen Swisher</i>
3:21 PM	Identifying oligometastatic disease likely to benefit from radiation therapy	<i>Jillian Tsai</i>
3:28 PM	Sequencing of radiation and immune checkpoint inhibition in head and neck cancer: Lessons learned	<i>Jonathan Schoenfeld</i>
3:35 PM	The potential role for radiation in SCLC	<i>Gregory Videtic</i>

3:42 PM **DISCUSSION**

6:00 PM **WELCOME DINNER**

FRIDAY, JULY 10, 2026, MORNING SESSIONS

6:00 AM **BREAKFAST**

TARGETING HER2 AND HER3 IN NSCLC

John Heymach

6:30 AM	DESTINY-Lung02 - Trastuzumab deruxtecan in patients With HER2-mutant metastatic NSCLC	<i>John Heymach</i>
6:37 AM	Combination trials in design or ongoing: Zongertinib and HER2-directed strategies	<i>Urs Weber</i>
6:44 AM	Izalontamab brengitecan (EGFRxHER3 ADC) in advanced EGFR-Mutated NSCLC	<i>Sid Devarakonda</i>
6:51 AM	Patritumab deruxtecan: Where are we?	<i>Julia Rotow</i>

6:58 AM **DISCUSSION**

EGFR TARGETING BISPECIFICS IN IN HEAD AND NECK CANCER

Everett Vokes

7:15 AM	Amivantamab as a therapeutic approach to HNSCC	<i>Renata Ferrarotto</i>
7:22 AM	Petosemtamab, an EGFR/LGR5 bispecific, in HNSCC	<i>Everett Vokes</i>
7:29 AM	Ficerafusp alfa, a bispecific antibody targeting EGFRxTGF- β , in HNSCC	<i>Assuntina (Tina) Sacco</i>

7:36 AM **DISCUSSION**

NEOADJUVANT AND ADJUVANT TRIALS WITH AGENTS TARGETING KRAS G12C MUTATIONS

Mara Antonoff

7:50 AM	Optimizing perioperative therapy for KRAS G12C-mutated NSCLC: Emerging KRAS inhibitor combination approaches	<i>Haniel Araujo</i>
7:57 AM	Ongoing trials with olomorasib in the perioperative setting for KRAS G12C-mutated NSCLC	<i>Timothy Burns</i>
8:04 AM	Findings from divarasib in the neoadjuvant setting for KRAS G12C NSCLC	<i>Jamie Chافت</i>
8:11 AM	Ongoing adjuvant divarasib trials in KRAS G12C early stage NSCLC	<i>Jay Lee</i>

8:18 AM **DISCUSSION**

TARGETING B7H3 IN SCLC

Sandip Patel

8:35 AM	Ifinatamab deruxtecan in previously treated ES-SCLC	<i>Lauren Byers</i>
8:42 AM	Emerging ADCs targeting B7H3 in lung cancer	<i>Millie Das</i>
8:49 AM	Emerging data for YL201, a B7H3-targeted ADC in development for lung cancer	<i>Jeff Petty</i>
8:56 AM	First-in-human regulatable B7H3 CAR T-cell therapy (SNP CAR)	<i>Allison Betof</i>

9:03 AM **DISCUSSION**

9:20 AM **BREAK**

SCREENING AND ENVIRONMENTAL ISSUES

Lawson Eng

9:40 AM	What is the role for early disease screening in nonsmokers with high-risk family history?	<i>Jamie Chافت</i>
9:47 AM	Advances in diagnosis and staging of lung cancer using robotic bronchoscopy	<i>Matthew Bott</i>
9:54 AM	Organizing a screening program for nonsmokers at high risk for lung cancer	<i>Elaine Shum</i>
10:01 AM	Environmental pollution and wildfires and pathogenesis and outcomes in lung cancer	<i>Surbhi Singhal</i>
10:08 AM	Evaluation of geospatial particulate matter in Rhode Island and its link to increased lung cancer risks	<i>Hina Khan</i>
10:15 AM	The nuance of nodules – The dilemma of managing multiple ground glass opacities	<i>James Huang</i>

10:22 AM **DISCUSSION**

ADVANCES IN RADIATION TECHNOLOGY AND THERANOSTICS

Jonathan Schoenfeld

10:45 AM	Role of radiation in patients with multiple metastatic lesions who are getting active therapy	<i>Jillian Tsai</i>
10:52 AM	Optimizing hypofractionated radiation therapy for stage III NSCLC	<i>Percy Lee</i>
10:59 AM	Can we give single-dose SBRT to treat lung cancer?	<i>Gregory Videtic</i>
11:06 AM	What is the current role for protons in current lung and thoracic tumors?	<i>James Urbanic</i>
11:13 AM	Hafnium oxide nanoparticle as radiation sensitizers	<i>Steven Lin</i>
11:20 AM	Biology-guided radiation therapy for lung cancer	<i>Henry Park</i>
11:27 AM	Tumor treating fields (TTF/Optune Lua, Novocure)	<i>Corey Langer</i>
11:34 AM	An overview of directed therapy with actinium in SCLC	<i>Bingnan Zhang</i>

11:41 AM **DISCUSSION**

FRIDAY, JULY 10, 2026, AFTERNOON SESSIONS

12:00 PM	WORKING LUNCH SESSION: INDUSTRY PIPELINE PRESENTATIONS (MODERATED BY VINAY JAIN)	<i>Vinay Jain</i>
12:10 PM	Boehringer Ingelheim	<i>Audra Kammerer</i>
12:20 PM	Amgen: SCLC pipeline	<i>Amanda Struckhoff</i>
12:30 PM	BioNTech	<i>Claudia-Nanette Gann</i>
12:40 PM	Nuvation Bio	<i>Ben Thompson</i>
12:50 PM	Gilead	<i>Ravi Gupta</i>

SYNERGISTIC AGENTS WITH CHECKPOINT INHIBITORS
Valsamo Anagnostou

1:00 PM	The biological rationale for targeting CTLA4 in NSCLC patients with STK11 mutations	<i>Biagio Ricciuti</i>
1:07 PM	Ivonescimab (PD-1 X VEGF Bispecific): Ongoing trials in NSCLC	<i>Xiuning Le</i>
1:14 PM	BNT324 + pumitamidg (BNT327) combination in advanced lung cancer	<i>Mehmet Altan</i>
1:21 PM	PF 08634404: (PD-1 X VEGF bispecific) in squamous and non-squamous NSCLC	<i>Natasha Leighl</i>
1:28 PM	ATR inhibitor ceralasertib (C) + durvalumab (D) after anti-PD-(L)1 therapy	<i>John Heymach</i>
1:35 PM	Genomic markers of metastasis and metastatic sites in NSCLC	<i>Brendan Knapp</i>

1:42 PM DISCUSSION

PERIOPERATIVE THERAPY
Jay Lee

2:00 PM	Neoadjuvant therapy approaches for unresectable stage III non-small cell lung cancer	<i>Everett Vokes</i>
2:07 PM	Ultra-sensitive ctDNA MRD approaches for treatment optimization in resectable NSCLC	<i>Valsamo Anagnostou</i>
2:14 PM	ctDNA in stage I disease	<i>Natasha Leighl</i>
2:21 PM	Central disease SBRT with MRI-guided radiation for NSCLC	<i>Percy Lee</i>
2:28 PM	My experience with post-targeted therapy resection in lung cancer	<i>Erin Gillaspie</i>
2:35 PM	An update on surgical interventions in the NORTHSTAR trial	<i>Mara Antonoff</i>
2:42 PM	Using ctDNA to guide radiation discontinuation for patients with head and neck cancer	<i>Jonathan Schoenfeld</i>

2:49 PM DISCUSSION

GENOMICS/EPIGENOMICS/PROTEOMICS/METABOLOMICS
Ravi Salgia

3:05 PM	Circulating giant cells that may drive metastasis	<i>Steven Lin</i>
3:12 PM	Transcriptomic evaluation of the genomics of relapse in SCLC	<i>Brendan Knapp</i>
3:19 PM	Biomarker-driven age assessment to expand enrollment of older adults	<i>Surbhi Singhal</i>
3:26 PM	Progress in predicting response to checkpoint inhibitors using transcriptomic profiling	<i>Dhruv Bansal</i>
3:33 PM	DISCUSSION	

SATURDAY, JULY 11, 2026, MORNING SESSIONS

6:00 AM **BREAKFAST**

PATIENT QUALITY OF LIFE
Ken Culver

6:30 AM	Tobacco control & survivorship	Lawson Eng
6:37 AM	Palliative care as an essential component of patient care in the advanced disease setting	Fionnuala Crowley
6:44 AM	Optimizing approaches to treating and preventing cancer cachexia, ponsegromab (PF-06946860): A GDF-15 antibody	Mary Jo Fidler
6:51 AM	Role of pulmonary rehabilitation in optimizing quality of life in metastatic NSCLC survivors	Melinda Hsu
6:58 AM	DISCUSSION	

VACCINES AND CELLULAR THERAPY AND ONCOLYTIC VIRUS
Matthew Gumbleton

7:15 AM	Cellular therapies in development for lung cancer and mesothelioma targeting EGFR and mesothelin (A2B694 and A2B395)	Antonious Hazim
7:22 AM	mRNA vaccines boosting cancer immunotherapy by activating the immune system, with early evidence of improved outcomes	Steven Lin
7:29 AM	Engineered TIL therapy for NSCLC using Obsidian Therapeutics' platform	Allison Betof
7:36 AM	BNT116: mRNA vaccine targeted tumor associated antigens	Zhonglin Hao
7:43 AM	The potential role for RAS vaccines for eliminating MRD in KRAS-mutated patients	Haniel Araujo
7:50 AM	Evidence for an intratumoral HA3 oncolytic virus for overcoming immune resistance in relapsed/refractory metastatic NSCLC	Jun Zhang
7:57 AM	DISCUSSION	

NEUROENDOCRINE CARCINOMAS
Misty Shields

8:15 AM	Defining neuroendocrine carcinoma as a pathologic entity and optimizing treatment approaches	Jeff Petty
8:22 AM	Molecular profiling of pulmonary large cell neuroendocrine carcinoma	Umit Tapan
8:29 AM	Pathogenesis and clinical presentation for invasive mucinous adenocarcinoma	Matthew Gumbleton
8:36 AM	Perioperative strategies in high-grade neuroendocrine carcinoma	Jay Lee
8:43 AM	DISCUSSION	

MESOTHELIOMA
Matthew Bott

9:00 AM	Emerging surgical approaches to mesothelioma	Marc de Perrot
9:07 AM	Using SW-682 to target YAP-TEAD and the Hippo pathway as a treatment approach for mesothelioma	Sandip Patel
9:14 AM	VT3989 and SW-682: TEAD as a therapeutic target in mesothelioma	Arjan Gower
9:21 AM	SynKIR-110 mesothelin KIR-CAR T for mesothelioma	Mehmet Altan
9:28 AM	Evidence for tumor treating fields in progressing mNSCLC and mesothelioma	Jun Zhang
9:35 AM	DISCUSSION	

AI AND MACHINE LEARNING
Sandip Patel

9:50 AM	Digital twin AI foundation model for lung cancer	John Heymach
9:57 AM	An AI-based approach to guide repurposing of treatments for tumors resistant to a prior targeted therapy	Vivek Behera
10:04 AM	Machine learning technologies to predict and detect myocarditis	Abdul Rafah Naqash
10:11 AM	Using AI to score radiological responses in lung cancer trials	Dhruv Bansal
10:18 AM	AI/ML integration into genomic and clinical datasets to detect signals missed by conventional review	Sid Devarakonda
10:25 AM	DISCUSSION	

OTHER TARGETS
Mary Jo Fidler

10:40 AM	Chitinase-3-like protein 1 (CHI3L1) inhibitor as a potential treatment for lung cancer	Hina Khan
10:47 AM	Early data for a bispecific targeting MUC16 x CD3	Mary Jo Fidler
10:54 AM	REM-422, an mRNA degrader targeting MYB and current data in adenoid cystic carcinoma	Renata Ferrarotto
11:01 AM	DISCUSSION	

PREDICTING ICI RESPONSE AND NOVEL SYNERGISTIC AGENTS
Natasha Leighl

11:25 AM	Spatial biology approaches to determine probability of response to immune checkpoint inhibitors for NSCLC	Vivek Behera
11:32 AM	Impact of antibiotic use on ICI efficacy	Lawson Eng
11:39 AM	Translational biomarker pipeline for TIL patients — single-cell TCR-seq, 57-color flow cytometry, and spatial transcriptomics (Xenium)	Allison Betof
11:46 AM	DISCUSSION	
12:00 PM	DISPERSALS	